Zealand CEO On Amylins And Obesity: We’re Not Following Novo, We Have Our Own Narrative

Adam Steensberg talked to Scrip about his firm’s vision for obesity treatment, Zealand’s independence from neighbor Novo Nordisk, and the hunt for a partner for its amylin candidate, petrelintide.